Sign In
Buy AERI
$15.25
+0 (+0%)
At Close: Feb 17, 2023
Aerie Pharmaceuticals (NASDAQ:AERI) PT Lowered to $26.00 at Oppenheimer
01:24pm, Monday, 13'th Apr 2020
Aerie Pharmaceuticals (NASDAQ:AERI) had its price objective dropped by analysts at Oppenheimer from $28.00 to $26.00 in a research note issued on Monday, BenzingaRatingsTable reports. The firm current
Needham & Company LLC Reiterates "Buy" Rating for Aerie Pharmaceuticals (NASDAQ:AERI)
11:58am, Monday, 13'th Apr 2020
Aerie Pharmaceuticals (NASDAQ:AERI)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research report issued to clients and investors on Monday, AnalystRatings.com reports. T
Oppenheimer Thinks Aerie Pharma's Stock is Going to Recover
11:07am, Monday, 13'th Apr 2020
Oppenheimer analyst Esther Rajavelu maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $26.00. The company's shares closed
Oppenheimer Thinks Aerie Pharma’s Stock is Going to Recover
11:07am, Monday, 13'th Apr 2020
Oppenheimer analyst Esther Rajavelu maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Expected to Announce Earnings of -$0.72 Per Share
10:40am, Monday, 13'th Apr 2020
Brokerages expect Aerie Pharmaceuticals Inc (NASDAQ:AERI) to post earnings per share (EPS) of ($0.72) for the current quarter, Zacks reports. Six analysts have provided estimates for Aerie Pharmaceuti
Analysts Offer Insights on Healthcare Companies: Aerie Pharma (AERI) and Neurocrine (NBIX)
09:51am, Monday, 13'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (AERI) and Neurocrine (NBIX) with bullish
Analysts Offer Insights on Healthcare Companies: Aerie Pharma (NASDAQ: AERI) and Neurocrine (NASDAQ: NBIX)
09:51am, Monday, 13'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (
AERI
–
Research Report
) and Neurocrine (
NBIX
–
Research Report
) with bullish sent
Aerie Pharma (AERI) Receives a Buy from Mizuho Securities
01:59am, Monday, 13'th Apr 2020
In a report released yesterday, Difei Yang from Mizuho Securities maintained a Buy rating on Aerie Pharma (AERI), with a price target of $54.00. The
Aerie Pharma (AERI) Receives a Buy from Mizuho Securities
01:59am, Monday, 13'th Apr 2020
In a report released yesterday, Difei Yang from Mizuho Securities maintained a Buy rating on Aerie Pharma (AERI – Research
So far Sunday, April 12, NASDAQ is down -0.19% and the S&P is up 0.63%. Let’s take a look at
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Expected to Post Quarterly Sales of $21.03 Million
06:46am, Sunday, 12'th Apr 2020
Analysts expect that Aerie Pharmaceuticals Inc (NASDAQ:AERI) will report $21.03 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates f
Aerie Pharmaceuticals (NASDAQ:AERI) Upgraded to "Sell" at BidaskClub
08:58am, Saturday, 11'th Apr 2020
Aerie Pharmaceuticals (NASDAQ:AERI) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday, BidAskClub repo
Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19
08:01pm, Thursday, 09'th Apr 2020
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients w
Aerie Pharmaceuticals withdraws FY20 guidance AERI
09:02am, Thursday, 09'th Apr 2020
Aerie Pharmaceuticals withdraws FY20 guidance AERI
